These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 26460822

  • 1. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage.
    Crane GM, Powell H, Kostadinov R, Rocafort PT, Rifkin DE, Burger PC, Ambinder RF, Swinnen LJ, Borowitz MJ, Duffield AS.
    Oncotarget; 2015 Oct 20; 6(32):33849-66. PubMed ID: 26460822
    [Abstract] [Full Text] [Related]

  • 2. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV.
    Transplantation; 2012 Jan 15; 93(1):73-81. PubMed ID: 22129761
    [Abstract] [Full Text] [Related]

  • 3. Posttransplant lymphoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil.
    Funch DP, Ko HH, Travasso J, Brady J, Kew CE, Nalesnik MA, Walker AM.
    Transplantation; 2005 Nov 15; 80(9):1174-80. PubMed ID: 16314782
    [Abstract] [Full Text] [Related]

  • 4. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
    Rabot N, Büchler M, Foucher Y, Moreau A, Debiais C, Machet MC, Kessler M, Morelon E, Thierry A, Legendre C, Rivalan J, Kamar N, Dantal J.
    Transpl Int; 2014 Sep 15; 27(9):956-65. PubMed ID: 24964147
    [Abstract] [Full Text] [Related]

  • 5. Susceptibility-weighted imaging and diffusion-weighted imaging findings in central nervous system monomorphic B cell post-transplant lymphoproliferative disorder before and after treatment and comparison with primary B cell central nervous system lymphoma.
    Ginat DT, Purakal A, Pytel P.
    J Neurooncol; 2015 Nov 15; 125(2):297-305. PubMed ID: 26341369
    [Abstract] [Full Text] [Related]

  • 6. [Primary central nervous system post-transplant lymphoproliferative disorders].
    Honda M, Koga M, Kanda T.
    Brain Nerve; 2014 Aug 15; 66(8):947-54. PubMed ID: 25082316
    [Abstract] [Full Text] [Related]

  • 7. Posttransplant lymphoproliferative disorder in a kidney-pancreas transplanted recipient: simultaneous development of clonal lymphoid B-cell proliferation of host and donor origin.
    Heyny-von Haussen R, Klingel K, Riegel W, Kandolf R, Mall G.
    Am J Surg Pathol; 2006 Jul 15; 30(7):900-5. PubMed ID: 16819335
    [Abstract] [Full Text] [Related]

  • 8. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
    Zimmermann H, Nitsche M, Pott C, Reinke P, Babel N, Hermann RM, Hauser IA, Hahn D, Ritgen M, Pietschmann C, Klapper W, Anagnostopoulos I, Trappe RU, German PTLD Study Group and German Lymphoma Alliance.
    Ann Hematol; 2021 Aug 15; 100(8):2043-2050. PubMed ID: 33973053
    [Abstract] [Full Text] [Related]

  • 9. Posttransplant lymphoproliferative disorders of the central nervous system after kidney transplantation: single center experience over 40 years. Two case reports.
    Arita H, Izumoto S, Kinoshita M, Okita Y, Hashimoto N, Fujita T, Ichimaru N, Takahara S, Yoshimine T.
    Neurol Med Chir (Tokyo); 2010 Aug 15; 50(12):1079-83. PubMed ID: 21206182
    [Abstract] [Full Text] [Related]

  • 10. EBV-positive post-transplant lymphoproliferative disorder presenting as primary diffuse large B-cell lymphoma of the central nervous system.
    Xu H, Rewerska J, Aardsma N, Slavin K, Valyi-Nagy T, Ni H.
    Folia Neuropathol; 2017 Aug 15; 55(3):221-226. PubMed ID: 28984115
    [Abstract] [Full Text] [Related]

  • 11. Primary Central Nervous System Post-transplant Lymphoproliferative Disorder Misdiagnosed as Glioblastoma: A Case Report.
    Tanaka H, Matsuda R, Nakamura M, Nakagawa I, Nakase H.
    Anticancer Res; 2022 Aug 15; 42(8):3975-3979. PubMed ID: 35896237
    [Abstract] [Full Text] [Related]

  • 12. A French Cohort Study of Kidney Retransplantation after Post-Transplant Lymphoproliferative Disorders.
    Caillard S, Cellot E, Dantal J, Thaunat O, Provot F, Janbon B, Buchler M, Anglicheau D, Merville P, Lang P, Frimat L, Colosio C, Alamartine E, Kamar N, Heng AE, Durrbach A, Moal V, Rivalan J, Etienne I, Peraldi MN, Moreau A, Moulin B, French PTLD Registry.
    Clin J Am Soc Nephrol; 2017 Oct 06; 12(10):1663-1670. PubMed ID: 28818847
    [Abstract] [Full Text] [Related]

  • 13. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S, Zafar MN, Best J, Reddy HK.
    J Cardiovasc Pharmacol Ther; 2006 Mar 06; 11(1):77-83. PubMed ID: 16703222
    [Abstract] [Full Text] [Related]

  • 14. [Remission induced by dose-reduction of immunosuppressants alone in a patient with post-transplant lymphoproliferative disorder of central nervous system origin].
    Minauchi K, Koizumi K, Kondo M, Takigami M, Harada H, Fujita H, Mukai M.
    Rinsho Ketsueki; 2011 May 06; 52(5):272-7. PubMed ID: 21646772
    [Abstract] [Full Text] [Related]

  • 15. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
    Grinyó JM, Gil-Vernet S, Cruzado JM, Caldés A, Riera L, Serón D, Rama I, Torras J.
    Transpl Int; 2003 Nov 06; 16(11):820-7. PubMed ID: 12879230
    [Abstract] [Full Text] [Related]

  • 16. Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials.
    Zimmermann H, Babel N, Dierickx D, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Bachy E, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S, Trappe RU.
    Transplantation; 2018 Nov 06; 102(11):1914-1923. PubMed ID: 29757894
    [Abstract] [Full Text] [Related]

  • 17. Short-term decreased post transplant lymphoproliferative disorder risk after kidney transplantation using two novel regimens.
    Chiodo Ortiz A, Petrossian G, Addonizio K, Hsiao A, Koizumi N, Yu Y, Plews R, Conti D, Ortiz J.
    Transpl Immunol; 2023 Feb 06; 76():101774. PubMed ID: 36528248
    [Abstract] [Full Text] [Related]

  • 18. Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report.
    Cavaliere R, Petroni G, Lopes MB, Schiff D, International Primary Central Nervous System Lymphoma Collaborative Group.
    Cancer; 2010 Feb 15; 116(4):863-70. PubMed ID: 20052713
    [Abstract] [Full Text] [Related]

  • 19. Very late onset lymphoproliferative disorders occurring over 10 years post-renal transplantation: PTLD.Int. Survey.
    Khedmat H, Taheri S.
    Hematol Oncol Stem Cell Ther; 2011 Feb 15; 4(2):73-80. PubMed ID: 21727768
    [Abstract] [Full Text] [Related]

  • 20. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.
    J Heart Lung Transplant; 2008 Jan 15; 27(1):100-5. PubMed ID: 18187094
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.